Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement